The Brand Name CYKLOKAPRON Has Generic Salt :: Tranexamic 

CYKLOKAPRON  Is From Company Pfizer Priced :: Rs. 166.11

CYKLOKAPRON have Tranexamic is comes under Sub class Hemostatics,Hemorrheologic of  Main Class Hematological System

Main Medicine Class:: Hematological System  Sub Medicine Class :: Hemostatics,Hemorrheologic 

Indications for Drugs ::

Haemorrhage, Hereditary angioedema

Drug Dose ::

Adult: PO Short-term management of haemorrhage 1-1.5 g 2-3 times/day. Long-term management of hereditary angioedema 1-1.5 g 2-3 times/day. Child: 25 mg/kg bid or tid. IV Short-term management of haemorrhage 0.5-1 g 3 times/day. Child: 10 mg/kg bid or tid.

Contraindication ::

Severe renal failure, active intravascular clotting, thromboembolic disease, colour vision disorders, subarachnoid bleeding.

Drug Precautions ::

Mild to moderate renal impairment, irregular menstrual bleeding, previous history of thromboembolic disease, haematuria. Monitor closely in disseminated intravascular coagulation. Monitor LFT and eye examination regularly during long-term use. Discontinue if disturbance in colour vision occurs. Avoid IV inj rate >1 ml/minute due to risk of hypotension. Pregnancy, lactation.

Drug Side Effects ::

Diarrhoea, nausea, vomiting, disturbances in colour vision, giddiness, hypotension (after rapid IV inj), thromboembolic events.

Pregnancy category ::

2

Drug Mode of Action ::  

Tranexamic acid is an antifibrinolytic agent that competitively inhibits breakdown of fibrin clots. It blocks binding of plasminogen and plasmin to fibrin, thereby preventing haemostatic plug dissolution.

Drug Interactions ::

Potentially Fatal: Increased risk of thrombus formation with estrogens, Factor IX complex concentrates or anti-inhibitor coagulant concentrates. Increased risk of fatal thrombotic complications with tretinoin in acute promyelocytic leukaemia.